Oppenheimer Keeps Their Buy Rating on Catalyst Pharma (CPRX)

By Jason Carr

In a report released today, Leland Gershell from Oppenheimer reiterated a Buy rating on Catalyst Pharma (CPRXResearch Report), with a price target of $9. The company’s shares closed yesterday at $2.91.

Gershell observed:

“CPRX traded down sharply yesterday following a Reuters article that discussed a letter from Senator Bernie Sanders (I-VT) to HHS and FDA Commissioner Scott Gottlieb. The shares closed down 5.8% on relatively heavy volume. While Sanders’ call to effectively allow compounded forms of 3,4-DAP may have spooked the market, we view this merely as headline noise, as we ascribe a near-zero likelihood that the agency would act in contradiction to its own recent guidance (issued under Gottlieb/Azar). We continue to expect Firdapse’s launch in LEMS to at least meet expectations, and view the current weakness as an attractive buying opportunity.”

According to TipRanks.com, Gershell is a 1-star analyst with an average return of -1.1% and a 37.5% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Evofem Biosciences Inc, AzurRx BioPharma Inc, and Urogen Pharma Ltd.

Currently, the analyst consensus on Catalyst Pharma is a Strong Buy with an average price target of $8.38.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.05 and a one-year low of $1.85. Currently, Catalyst Pharma has an average volume of 1.39M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette’s disorder.